MRK

Merck & Co Inc

Feb 03 • 04:00PM ET

115.84

+2.47 2.18 %

Healthcare • Drug Manufacturers - General • USA • NYSE

Feb 03, 12:45 PMMerck posts Q4 2025 beat (sales $16.4B, non-GAAP EPS $2.04) and FY2025 results (sales $65.0B, EPS $8.98), issues 2026 guidance of EPS $5.00-$5.15 and revenue $65.5B-$67B, with shares down on a below-consensus outlook that assumes no Gardasil shipments to China; it says the 2026 EPS guide includes a one-time $9B ($3.65/share) charge from the Cidara Therapeutics acquisition.

Peers: PFE AZN-D NVS BMY JNJ AMGN ABBV GSK LLY SNY

| Held by: VTI VOO IVV SPY SCHD VTV XLV VIG VYM VHT

Scroll to Statements

Index	DJIA, S&P 500	P/E	15.92	EPS (ttm)	7.28	Insider Own	0.11%	Shs Outstand	2.48B	Perf Week	7.34%
Market Cap	287.52B	Forward P/E	11.82	EPS next Y	9.80	Insider Trans	-0.57%	Shs Float	2.48B	Perf Month	8.82%
Enterprise Value	310.70B	PEG	2.05	EPS next Q	-1.44	Inst Own	79.59%	Short Float	1.36%	Perf Quarter	34.73%
Income	18.25B	P/S	4.42	EPS this Y	-41.44%	Inst Trans	-1.47%	Short Ratio	2.40	Perf Half Y	45.05%
Sales	65.00B	P/B	5.56	EPS next Y	86.36%	ROA	15.41%	Short Interest	33.65M	Perf YTD	10.05%
Book/sh	20.85	P/C	15.76	EPS next 5Y	5.76%	ROE	39.51%	52W High	113.89 1.71%	Perf Year	17.22%
Cash/sh	7.35	P/FCF	22.03	EPS past 3/5Y	8.43% 21.23%	ROIC	19.88%	52W Low	73.31 58.01%	Perf 3Y	9.93%
Dividend Est.	3.25 (2.80%)	EV/EBITDA	10.41	Sales past 3/5Y	3.60% 9.37%	Gross Margin	81.50%	Volatility	3.34% 2.62%	Perf 5Y	57.63%
Dividend TTM	3.28 (2.83%)	EV/Sales	4.78	EPS Y/Y TTM	58.02%	Oper. Margin	41.18%	ATR (14)	2.87	Perf 10Y	136.12%
Dividend Ex-Date	Mar 16, 2026	Quick Ratio	1.44	Sales Y/Y TTM	1.61%	Profit Margin	28.08%	RSI (14)	70.43	Recom	1.97
Dividend Gr. 3/5Y	5.73% 6.66%	Current Ratio	1.66	EPS Q/Q	-19.28%	SMA20	5.54%	Beta	0.30	Target Price	118.96
Payout	45.05%	Debt/Eq	0.80	Sales Q/Q	7.24%	SMA50	10.19%	Rel Volume	1.82	Prev Close	113.37
Employees	75000	LT Debt/Eq	0.77	Earnings	Feb 03 BMO	SMA200	31.32%	Avg Volume	14.04M	Price	115.84
IPO	Jun 15, 1946	Option/Short	Yes / Yes	EPS/Sales Surpr.	1.43% 1.24%	Trades		Volume	25,606,050	Change	2.18%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-08-26	Upgrade	Wolfe Research	Peer Perform → Outperform	$135
Dec-18-25	Upgrade	BMO Capital Markets	Market Perform → Outperform	$130
Nov-24-25	Upgrade	Wells Fargo	Equal Weight → Overweight	$125
Nov-13-25	Initiated	Scotiabank	Sector Outperform	$105
Oct-13-25	Resumed	Citigroup	Neutral	$95
Sep-17-25	Downgrade	Berenberg	Buy → Hold	$90
May-14-25	Downgrade	Citigroup	Buy → Neutral	$84
Apr-22-25	Initiated	Cantor Fitzgerald	Neutral	$85
Feb-18-25	Downgrade	Deutsche Bank	Buy → Hold	$128 → $105
Feb-10-25	Downgrade	TD Cowen	Buy → Hold	$121 → $100
Jan-08-25	Downgrade	Truist	Buy → Hold	$110
Dec-20-24	Downgrade	BMO Capital Markets	Outperform → Market Perform	$136 → $105
Dec-10-24	Resumed	BofA Securities	Buy	$121
Dec-04-24	Upgrade	HSBC Securities	Hold → Buy	$130
Nov-15-24	Initiated	Wolfe Research	Peer Perform
Nov-11-24	Downgrade	Daiwa Securities	Buy → Neutral
Oct-17-24	Initiated	Bernstein	Mkt Perform	$115
Mar-11-24	Downgrade	Societe Generale	Hold → Sell	$104
Jan-04-24	Upgrade	TD Cowen	Market Perform → Outperform	$125 → $135
Nov-09-23	Initiated	Deutsche Bank	Buy	$115

Show Previous Ratings

Feb-03-26 04:36PM	These Stocks Are Todays Movers: Palantir, Pfizer, AMD, PayPal, Novo Nordisk, PepsiCo, Merck, and More (Barrons.com)
04:26PM	Stocks Tumble on AI Disruption Fears (Barchart)
04:02PM	Merck & Co Inc (MRK) Q4 2025 Earnings Call Highlights: Strong Growth Amidst Challenges (GuruFocus.com)
03:42PM	Analyst Report: Merck & Co., Inc. (Morningstar Research)
02:56PM	Pfizer Stock Falls After Solid Earnings. Whats Troubling Wall Street. (Barrons.com)
02:43PM	Loading…
02:43PM	Merck Stock Gains as Earnings Top Estimates. Momentum Is Building, Says CEO. (Barrons.com)
12:40PM	MSDs 2026 sales forecast falls short amid patent losses despite strong Q4 (Pharmaceutical Technology)
12:30PM	Dow Hits Record, Nasdaq Sinks as Tech Stocks Retreat (GuruFocus.com)
12:18PM	Merck 2026 Outlook Misses as Gardasil Sales Drop 35% (GuruFocus.com)
12:15PM	Dow's Early Record Fades as Tech Turns South (Schaeffer's Research)
11:36AM	MRK Q4 Earnings & Sales Beat Estimates, Stock Down on Weak '26 View (Zacks)
11:06AM	Merck's Annual Outlook Falls Short But Keytruda, Animal Health Segments Grow (Benzinga)
11:04AM	2 Pharma Stocks React to Quarterly Results, Guidance (Schaeffer's Research)
11:00AM	Merck (MRK) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
11:00AM	Market Awaits JOLTS Jobs Report (Zacks)
10:26AM	Loading…
10:26AM	Q4 Earnings, JOLTS & a Changing of the Disney Guard (Zacks)
10:17AM	Stock Market Today: Dow Inches Higher As Palantir Rallies; Rambus Tumbles (Live Coverage) (Investor's Business Daily)
09:27AM	Here's Why Gilead Sciences Stock Surged 21% in a Month (Zacks)
08:19AM	Pharma stocks slump as Pfizer and Merck report earnings (Quartz)
08:19AM	Merck and Pfizer decline vs the broader market as results released (Quartz)
07:40AM	Merck (MRK) Q4 Earnings and Revenues Beat Estimates (Zacks)
07:24AM	Jim Cramer on Merck & Co.: "I Think It Can Spread Out the Wealth" (Insider Monkey)
07:11AM	Merck shares fall as 2026 guidance disappoints despite solid Q4 results (Investing.com)
06:55AM	Merck's outlook for 2026 comes in lower-than-expected as pipeline faces make-or-break year (MarketWatch)
06:48AM	Merck's (NYSE:MRK) Q4 CY2025 Sales Beat Estimates (StockStory)
06:48AM	Merck Earnings Top Estimates. Why the Stock Is Falling. (Barrons.com)
06:40AM	Merck: Q4 Earnings Snapshot (Associated Press Finance)
06:30AM	Merck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results; Highlights Progress Advancing Broad, Diverse Pipeline (Business Wire)
05:51AM	Stocks to Watch Tuesday: Palantir, Teradyne, AMD (The Wall Street Journal)
05:00AM	Advanced Micro Devices heads earnings slate (MarketWatch)
04:34AM	Loading…
04:34AM	Where is Merck & Co. (MRK) Headed According to Wall Street? (Insider Monkey)
04:19AM	Stock Market Today: S&P 500 eyes fresh record as Dow and Nasdaq also called higher; Palantir rises after earnings; gold and silver rebound; AMD results on tap. (MarketWatch)
03:01AM	Big Tech and Pharma Earnings: What to Watch This Week (The Wall Street Journal)
Feb-02-26 07:00PM	AMD earnings, Netflix-Warner Bros. hearing: What to Watch (Yahoo Finance Video)
06:02PM	Big Tech and Pharma Earnings: What to Watch This Week (The Wall Street Journal)
05:46PM	Market Indexes Bounce Back to Start a New Trading Week (Zacks)
11:40AM	Merck Reports Earnings Tuesday Morning After Gaining 13% Over the Past Year (24/7 Wall St.)
11:12AM	Market Awaits January Manufacturing Numbers (Zacks)
10:35AM	Six More Weeks of Q4 Earnings Season? (Zacks)
10:25AM	What's in Store for These 5 Pharma Bigwigs This Earnings Season? (Zacks)
08:29AM	Palantir, AMD, Amazon and More Stocks with Earnings This Week (Benzinga)
07:00AM	Option Volatility And Earnings Report For February 2 - 6 (Barchart)
02:13AM	Jobs Report, Big Tech and Pharma Earnings: What to Watch This Week (The Wall Street Journal)
Feb-01-26 10:04PM	Merck (MRK) Q4 Earnings Report Preview: What To Look For (StockStory)
07:47AM	January jobs data, Alphabet and Amazon earnings, more Warsh fallout: What to watch this week (Yahoo Finance)
Jan-31-26 12:35PM	Merck & Co., Inc. (MRK) Joins BofA's "US 1 List" (Insider Monkey)
Jan-30-26 05:45PM	Merck (MRK) Advances While Market Declines: Some Information for Investors (Zacks)
04:57PM	Jobs Report, More Tech Earnings: What to Watch Next Week (The Wall Street Journal)
12:36PM	This Pharma Stock Eyes Entries, Battles For Key Level Amid 68% Earnings Growth (Investor's Business Daily)
09:41AM	Merck & Co. Stock Outlook: Is Wall Street Bullish or Bearish? (Barchart)
09:09AM	Stock Market Today: Dow Falls On Surprise Inflation Data, Warsh Nomination; Tesla Rallies (Live Coverage) (Investor's Business Daily)
08:49AM	Will BMY's Oncology Collaborations Drive Its Next Growth Phase? (Zacks)
07:50AM	Buy, Sell or Hold MRK Stock: Key Factors to Watch Before Q4 Earnings (Zacks)
03:51AM	Heard on the Street Thursday Recap: Gold Swings (The Wall Street Journal)
Jan-29-26 05:50PM	Why the Market Dipped But Merck (MRK) Gained Today (Zacks)
12:28PM	FDA Accepts Summit's Lung Cancer Drug Application, Review Underway (Benzinga)
09:15AM	Curious about Merck (MRK) Q4 Performance? Explore Wall Street Estimates for Key Metrics (Zacks)
09:00AM	Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
Jan-28-26 09:05PM	This Stock Is Already Up 58% This Year. Is It a Buy? (Motley Fool)
12:47PM	Pharma Stocks Are Close to 'Breaking Out.' Earnings Could Set Them Free. (Barrons.com)
10:15AM	Merck's Non-Oncology Drugs Q4 Performance: What to Expect (Zacks)
10:00AM	AbbVie (ABBV) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
09:30AM	Brokers Suggest Investing in Merck (MRK): Read This Before Placing a Bet (Zacks)
Jan-27-26 03:07PM	Merck Announces Second-Quarter 2026 Dividend (Business Wire)
02:51PM	3 Healthcare ETFs to Buy as Flat Medicare Rate Proposal Hits Insurers (Zacks)
12:51PM	Kazia Therapeutics Reports Positive Early Responses In Aggressive Breast Cancer Trial (Benzinga)
10:53AM	RVMD Stock Tumbles as MRK Reportedly Withdraws Buyout Offer (Zacks)
10:50AM	Registration-Ready: How 2026's Clinical Leaders Are Beating Cancer Benchmarks (PR Newswire)
10:45AM	Pfizer, Merck, CoreWeave, Zoom: Top Analyst Calls (Yahoo Finance Video)
10:37AM	2 Pharmaceutical Stocks Set to Rebound in 2026 (Motley Fool)
10:00AM	Merck (MRK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
02:14AM	Merck's (MRK) Quality is Clear, but Growth Visibility Matters, TD Cowen Notes (Insider Monkey)
Jan-26-26 07:36PM	Why Revolution Medicines Stock Plummeted by Almost 17% Today (Motley Fool)
04:56PM	Stocks to Watch Monday Recap: CoreWeave, IonQ, USA Rare Earth, RevMed (The Wall Street Journal)
01:48PM	Stocks to Watch Monday: CoreWeave, IonQ, USA Rare Earth, RevMed (The Wall Street Journal)
01:12PM	Stock Market Today: Trump's Medicare announcement slams health insurers (TheStreet)
12:47PM	Merck Ends Acquisition Talks With Revolution Medicines After Valuation Dispute (GuruFocus.com)
11:15AM	Moderna (MRNA) Stock Pulls Back After Recent Strength (Benzinga)
09:09AM	Revolution Medicines stock falls after Merck reportedly ends acquisition pursuit (Investing.com)
07:52AM	Why Is Cancer Drug Developer Erasca Stock Trading Lower Monday? (Benzinga)
07:19AM	MSD ends takeover talks with Revolution Medicines (Pharmaceutical Technology)
06:01AM	Revolution Medicines Stock Sinks After Merck Deal Talks Collapse (Benzinga)
04:00AM	Synthesia hits $4B valuation, lets employees cash out (TechCrunch)
Jan-25-26 02:43PM	Merck No Longer In Talks With Revolution Medicines: WSJ (Barrons.com)
02:30PM	Merck No Longer in Talks to Buy Revolution Medicines (The Wall Street Journal)
09:14AM	Merck & Co., Inc. (MRK) and CEPI Launch Effort to Make Ebola Vaccine Cheaper and Easier to Distribute (Insider Monkey)
04:46AM	Here Are the Top Four Blue-Chip Stocks To Buy in 2026, According to WarrenAI (Investing.com)
Jan-24-26 02:20PM	2 Under-the-Radar Biotech Stocks Set to Boom in 2026 (Motley Fool)
09:21AM	2 Dirt Cheap Stocks to Buy With $200 Right Now (Motley Fool)
Jan-23-26 01:05PM	Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead? (Motley Fool)
12:50PM	2 Soaring Stocks to Hold for the Next 20 Years (Motley Fool)
08:36AM	Here's How Eli Lilly's Oncology Drugs Are Poised Ahead of Q4 Earnings (Zacks)
01:30AM	AbbVie Dodged a Patent Disaster, and Shares Gained 460%. Merck and Bristol Myers Are Next. (Barrons.com)
Jan-22-26 05:02PM	These Stocks Are Todays Movers: Intel, GE Aerospace, Moderna, Abbott, Arista Networks, Mobileye, McCormick, and More (Barrons.com)
04:09PM	Moderna Stock Soars. This Has Sparked a Rally. (Barrons.com)
02:35PM	I Correctly Predicted That These 15 Dow Jones Stocks Would Boost Their Payouts in 2025. Here's Why It Can Happen Again in 2026. (Motley Fool)
02:02PM	Janux Therapeutics Strikes Bristol Myers Biotech Deal Worth $800 Million (Benzinga)
12:51PM	FDA Approves Guardant Health's Blood Test To Guide Treatment For Advanced Colorectal Cancer (Benzinga)
12:03PM	ABBV vs. MRK: An Oncology-Immunology Showdown for Investors (Zacks)
11:39AM	MRNA & MRK's Personalized Cancer Therapy Delivers Strong 5-Year Data (Zacks)

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Downing Cristal N	Chief Comm. & Public Afrs Ofcr	Nov 10 '25	Sale	87.00	7,085	616,395	0	Nov 12 04:01 PM
CRISTAL DOWNING	Officer	Nov 10 '25	Proposed Sale	87.00	7,085	616,395		Nov 10 04:07 PM
Williams David Michael	EVP,Chief Info&Digital Officer	Nov 03 '25	Sale	83.59	8,614	720,040	24,578	Nov 04 04:02 PM
DAVID WILLIAMS	Officer	Nov 03 '25	Proposed Sale	83.59	8,614	720,040		Nov 03 04:09 PM
Williams David Michael	EVP,Chief Info&Digital Officer	Aug 04 '25	Option Exercise	79.29	17,119	1,357,366	41,445	Aug 05 08:46 AM
Guindo Chirfi	Chief Marketing Officer	Aug 04 '25	Option Exercise	79.29	36,903	2,926,039	107,409	Aug 05 08:43 AM
Smart Dalton E. III	SVP Fin. - Global Controller	May 03 '25	Option Exercise	83.18	2,050	170,519	10,127	May 05 04:23 PM
Smart Dalton E. III	SVP Fin. - Global Controller	Apr 30 '25	Option Exercise	84.71	464	39,305	8,242	May 02 04:18 PM
Smart Dalton E. III	SVP Fin. - Global Controller	May 02 '25	Option Exercise	83.26	381	31,722	8,464	May 02 04:18 PM
Romanelli Joseph	President, Human Health Int?l	May 02 '25	Option Exercise	83.26	2,262	188,334	24,061	May 02 04:14 PM
Romanelli Joseph	President, Human Health Int?l	Apr 30 '25	Option Exercise	84.71	2,063	174,757	22,816	May 02 04:14 PM
Larson Betty D	EVP, Chief HR Officer	Apr 30 '25	Option Exercise	84.71	11,350	961,458	11,350	May 02 04:12 PM
Smart Dalton E. III	SVP Fin. - Global Controller	Apr 25 '25	Option Exercise	58.08	5,000	290,400	12,040	Apr 29 04:04 PM
Smart Dalton E. III	SVP Fin. - Global Controller	Apr 25 '25	Sale	82.76	4,262	352,723	7,778	Apr 29 04:04 PM
DALTON SMART	Officer	Apr 25 '25	Proposed Sale	82.76	4,262	352,723		Apr 25 04:05 PM
Oosthuizen Johannes Jacobus	President, U.S. Market	Feb 19 '25	Sale	84.09	8,500	714,745	30,705	Feb 20 04:01 PM
JOHANNES JACOBUS OOSTHUIZEN	Officer	Feb 19 '25	Proposed Sale	84.09	8,500	714,745		Feb 19 05:09 PM
DAVID WILLIAMS	Officer	Feb 13 '25	Proposed Sale	85.34	6,000	512,057		Feb 13 04:10 PM
Williams David Michael	EVP,Chief Info&Digital Officer	Feb 13 '25	Sale	85.34	6,000	512,057	24,123	Feb 13 04:01 PM
Oosthuizen Johannes Jacobus	President, U.S. Market	Feb 08 '25	Option Exercise	87.28	13,002	1,134,815	45,609	Feb 11 02:59 PM
THULIN INGE G	Director	Feb 06 '25	Buy	88.25	2,833	250,000	2,933	Feb 07 04:09 PM
Downing Cristal N	Chief Comm. & Public Afrs Ofcr	Feb 06 '25	Sale	88.76	2,361	209,551	7,085	Feb 07 04:07 PM
BAKER DOUGLAS M JR	Director	Feb 05 '25	Buy	88.50	15,000	1,327,500	16,000	Feb 07 04:04 PM
CRISTAL DOWNING	Officer	Feb 06 '25	Proposed Sale	88.76	2,361	209,551		Feb 06 04:43 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MRK

Merck & Co Inc

Upgrade your FINVIZ experience